ProfileGDS5678 / 1451554_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 89% 89% 88% 91% 89% 92% 90% 89% 91% 91% 90% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.3051291
GSM967853U87-EV human glioblastoma xenograft - Control 27.1186789
GSM967854U87-EV human glioblastoma xenograft - Control 36.9919689
GSM967855U87-EV human glioblastoma xenograft - Control 47.0224188
GSM967856U87-EV human glioblastoma xenograft - Control 57.4072391
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8212389
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.3682492
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2411690
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0724589
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.4753291
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4764491
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2622590
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3251391
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1987190